Insilico Medicine’s idiopathic pulmonary fibrosis drug led to dose-dependent improvement in lung function in a mid-stage study. Meanwhile, Pliant Therapeutics and PureTech Health are also making Phase 2 progress while Boehringer Ingelheim is planning regulatory submission supported by its IPF drug’s Phase 3 data.
The post AI-Designed Insilico Drug Flashes Signs of Efficacy in Lung Disease, But Rivals Are Still Ahead appeared first on MedCity News.
